Trial
NCT03024996
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Renal Cell Carcinoma
Intervention
Atezolizumab
Why stopped
The sponsor decided to terminate this study before the protocol-defined end-of-study, as permitted per protocol.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-03